Early Cancer Detection Test EarlyCDT®
EarlyCDT® is a simple blood test that detects the elevated presence of autoantibodies generated by the body’s immune system as a natural defense against cancer cells.
EarlyCDT® Lung is the world’s most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken in the community setting as well as a doctor’s surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT® Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2.
Autoantibodies can be detected in peripheral blood in patients with solid tumours up to 3–4 years before symptomatic presentation
Finger prink blood sample
- A sterile collection kit posted to your home containing easy to follow step-by-step instructions. You can view the kit instructions here.
- A simple, at-home finger-prick blood sample collection kit.
Lung Cancer in the UK
• Lung cancer kills 35,000 people every year in the UK accounting for 21% of
all cancer deaths making it one of the leading causes of cancer death in the
• Lung cancer is the third most common cancer in the UK. Around 48,500
people are diagnosed in the UK each year**
• Lung cancer is more common as you get older. Around 45% of those
diagnosed with lung cancer in the UK are aged 75+**
• More than 8 out of 10 cases of lung cancer in the UK are caused by smoking.**
If you have any of the risk factors listed below you should have the lung health screen:
- Heavy smokers
- Shisha and Marijuana smokers
- Passive smoking victim
- Family history of lung cancer
- Radiation exposure
- Asbestos exposure
- Chemical exposure and other carcinogens
- TB diagnosis
The Early detection of Cancer of the Lung Scotland (ECLS) trial conducted in Scotland with 12,208 patients, is believed to be the largest randomized controlled trial using blood biomarkers for the detection of lung cancer.
Results demonstrate the potential of Oncimmune’s EarlyCDT Lung blood test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.
In a randomized controlled trial of 12,208 people in Scotland at high risk of developing lung cancer, it was shown that more people were diagnosed at an early stage of the disease in the two years after having the EarlyCDT Lung blood test than those in the control arm who received standard clinical care.
The findings, presented at the 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC) in Barcelona, are an important validation of Oncimmune’s diagnostic platform technology which harnesses the power of the immune system, to detect evidence of the body’s natural response to cancer. The technology can detect cancer on average four years before standard clinical diagnosis.
Lung cancer was chosen as the first target of the technology because it is the world’s leading cause of cancer-related death and is often detected at an advanced stage with approximately 85% of patients in the UK undiagnosed until the disease has spread to other parts of the body.
Among those people who received the EarlyCDT Lung test and went on to develop lung cancer within the next two years, 41.1% were diagnosed at an early stage (stage 1&2) of the disease, compared with 26.8% among the control group subject to standard clinical practice. This resulted in a 36% reduction in late-stage presentation after 2 years of follow up in subjects randomized to the EarlyCDT blood test.
The trial also showed a lower rate of deaths among people in the intervention arm of the trial after two years compared with people in the control group. Lung cancer-specific deaths were also lower in the intervention group. This suggests that the EarlyCDT Lung blood test followed by CT imaging could produce a mortality benefit, although the trial was not powered to demonstrate such a trend after two years.
The results further validate the use of Oncimmune’s platform technology as a screening modality, which can detect cancer four years or more before standard clinical diagnosis. Oncimmune’s patented technology works by detecting the presence of autoantibodies generated by the body’s immune system as a natural defence against cancer cells.
5 days Laboratory days
(excluding transport time via Royal Mail)
1. Order EarlyCDT® LungEarlyCDT®
2.Receive EarlyCDT® LungEarlyCDT®
3. Produce finger prick sample
4. Post kit via Post box to labs
5. Results via password protected email
6. If you require any discussion pre or post results then an extra charge of £45 for GP consultation with our UK based Partner clinic is available. Please email on firstname.lastname@example.org. Any abnormal results will be discussed free of charge
Manufactured by Oncimmune and operates under an ISO 13485 accredited Quality Management System”
Early CDT are processed by UK labs CCL which is CPA and ISO 9001 Accreditation and UKAS accredited to the ISO15189 standard for medical laboratories.
Distributed in the UK by Biox Medical Ltd
EarlyCDT® LungEarlyCDT® shipped via RoyalMail Mail Tracked 24 to your home
There is a prepaid return bag included, please sample to your local post office or post box and this is shipped to our labs in the UK
The sample be processed by lab in 5 days. All shipping costs included.
We accept EarlyCDT® LungEarlyCDT® packages back for a full refund if it is returned within 14 days in an unused/undamaged condition. We cannot accept packages that has been damaged or used.
The kit must be used within 3 months otherwise stability and quality of the kit cannot be gauranteed and therefore void and cannot be refunded.
Pay online with secure online pay & paypal option available
EarlyCDT® LungEarlyCDT® can be claimed back from health insurance as a bowel cancer screening test (i.e BUPA, Geo Blue etc)